08:38 AM EST, 02/21/2025 (MT Newswires) -- Tiziana Life Sciences ( TLSA ) said Friday it has signed an agreement with contract development and manufacturing firm Renaissance Lakewood to produce foralumab in a nasal device.
Tiziana said it is evaluating intranasal foralumab in a phase 2a study to potentially treat neurodegenerative and inflammatory conditions.
Financial terms of the agreement were not disclosed.